Biologics Sales 2009: Antibodies are the growth drivers
Double digit growth rates in classes of antibodies and selected proteins
Among the 28 blockbuster biologics with 2009 sales of more than US$ 1 bln, the ophthalmic antibodyLucentis achieved the highest growth rate (+33% vs 2008) followed by the multiplesclerosis antibody Tysabri (+30%) and the insulin analogs Lantus (+22.5%) and NovoLog/NovoRapid (+22%). Anti-inflammatory antibodies different from anti-TNF were newly introduced as a class of biologics due to their strong growth potential (+36.5% vs 2008).
Biosimilar sales reported by Sandoz (US$ 118 mln) had no impact on 2009biologics sales, but showed a growth rate of 73%. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 12, 2010.
The document entitled “TOP 20 Biologics 2009” can be acquired as a free download.
Most read news
Organizations
Related link
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous